Long-term efficacy of olmesartan medoxomil in chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements

Clinical Drug Investigation

Volumn 32, Issue 11, 2012, Pages 729-734

  Wang, Ji Guang ^a   Sun, Ning Ling ^b   Ke, Yuan Nan ^c   Zhang, Bo Heng ^d   Ikegami, Naotaka ^e   Zhu, Jun Ren ^d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d FUDAN UNIVERSITY   (China)

^e DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; OLMESARTAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BLEEDING; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHINESE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; FOLLOW UP; GLOMERULONEPHRITIS; HEART INFARCTION; HOME MONITORING; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; LUMBAR DISK HERNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHI-SQUARE DISTRIBUTION; CHINA; HUMANS; HYPERTENSION; IMIDAZOLES; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; OFFICE VISITS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873450418     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-012-0003-7     Document Type: Article

References (14)

1. Zhu JR, Cai NS, Fan WH, Zhu DL, He B, Wu ZG, Ke YN, Guo JX, Ma H, Huang J, Li XL, Chen YZ. Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension. Chin J Cardiol (in Chinese). 2006;34:877-81.
2. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(283-91):318.
3. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003;23:419-30.
4. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:41-50.
5. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25:1327-36.
6. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 2003;17:425-32.
7. Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit. 2006;11:135-41.
8. Liau CS, Lee CM, Sheu SH, Ueng KC, Chien KL, Su TC, Lai WT, Lin MC, Lin CS, Lin CS. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in Chinese patients. Clin Drug Investig. 2005;25:473-9.
9. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig. 2006;26:185-93.
10. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther. 2004;26(Suppl A):A28-32.
11. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7:578-86.
12. Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag. 2006;2:327-40.
13. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T, O'Brien E, Ohkubo T, Padfield P, Palatini P, Pickering TG, Redon J, Revera M, Ruilope LM, Shennan A, Staessen JA, Tisler A, Waeber B, Zanchetti A, ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24:779-85.
14. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, American Heart Association, American Society of Hypertension, Preventive Cardiovascular Nurses Association. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:10-29.